author-photo

Nancy A. Dawson

Georgetown University
Walter Reed Army Medical Center

131

Papers

8376

Citations

Citation Trend

Filter By

Papers (131) Sort By

Journal Conference Others

688P Gene expression profiling (GEP) signatures associated with markers of sensitivity to immune and angiogenic therapy in clear-cell renal cell carcinoma (ccRCC) with sarcomatoid/rhabdoid features

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.

2021
Show All
- Source
- Cite
- Save
Citations (0)
Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy

2021 Frontiers in Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Patients’ preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation

2021 Urologic Oncology-seminars and Original Investigations
Show All
- Source
- Cite
- Save
Citations (0)
Cabozantinib plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer.

2020 BJUI
Show All
- Source
- Cite
- Save
Citations (1)
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.

2020 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (22)
Molecular profiling of aggressive variant urothelial carcinoma.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Non-urothelial bladder cancer: Genomic alterations and patient outcomes.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)